Leukocyte apheresis

Leukocyte apheresis
Specialty	Gastrointestinal

Leukocyte apheresis is a medical device therapy (selective granulocyte/monocyte adsorptive {GMA} apheresis; GMDN[1] code: 47306) for the treatment of inflammation of the colon. It works by removing from the blood a group of white blood cells called activated leukocytes[2] that play a key role in the inflammatory stages of ulcerative colitis (UC).[3] Selectively reducing these cells in the blood helps to reduce inflammation in the colon.[4] Leukocyte apheresis can help UC patients with chronic, grumbling disease who are either unsuitable for, intolerant of, or failing on medicines described above.[5]

References

"Global Medical Device Network". Archived from the original on 2014-08-15.
Hanai H.; et al. (January 2011). "The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review". Clinical & Experimental Immunology. 163 (1): 50–58. doi:10.1111/j.1365-2249.2010.04279.x. PMC 3010911. PMID 21078086.
Nikolaus S., Schreiber S.; et al. (April 1998). "Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation". Gut. 42 (4): 470–476. doi:10.1136/gut.42.4.470. PMC 1727082. PMID 9616306.
Muratov V.; et al. (2008). "Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis". Journal of Gastroenterology (43): 277–282.
Dignass A.; et al. (2015). "P511 Efficacy and safety of granulocyte/monocyte adsorptive apheresis in steroid-dependent Active Ulcerative Colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 24 and 48 weeks". ecco-ibd.eu. The European Crohn's and Colitis Organisation (ECCO).

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Global Medical Device Network". Archived from the original on 2014-08-15.

[2] Hanai H.; et al. (January 2011). "The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review". Clinical & Experimental Immunology. 163 (1): 50–58. doi:10.1111/j.1365-2249.2010.04279.x. PMC 3010911. PMID 21078086.

[3] Nikolaus S., Schreiber S.; et al. (April 1998). "Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation". Gut. 42 (4): 470–476. doi:10.1136/gut.42.4.470. PMC 1727082. PMID 9616306.

[4] Muratov V.; et al. (2008). "Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis". Journal of Gastroenterology (43): 277–282.

[5] Dignass A.; et al. (2015). "P511 Efficacy and safety of granulocyte/monocyte adsorptive apheresis in steroid-dependent Active Ulcerative Colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 24 and 48 weeks". ecco-ibd.eu. The European Crohn's and Colitis Organisation (ECCO).